The National Medical Commission (NMC) and the Indian Council of Medical Research (ICMR) recently issued a crucial advisory regarding stem cell therapy in India. This follows a significant Supreme Court judgment from January 30, 2026. Furthermore, this directive clarifies the permissible scope and regulatory framework for stem cell interventions. It particularly addresses a case involving therapy for Autism Spectrum Disorder (ASD).

Understanding the Supreme Court Directive on Stem Cell Therapy

The advisory stems from the Supreme Court's judgment in the matter of Yash Charitable Trust & Ors. versus Union of India & Ors. (W.P. (C) No. 369 of 2022). This landmark ruling has profound implications for how stem cell therapy is administered across India. Consequently, all medical colleges and institutions must ensure strict adherence to these new guidelines. The Supreme Court specifically stated that stem cell therapy for Autism Spectrum Disorder cannot be offered as a routine clinical service due to a lack of scientific evidence.

New Regulations for Routine Stem Cell Therapy in India

Moving forward, routine clinical practice now permits stem cell therapies only for disease conditions explicitly listed as "Standard Care" by the Ministry of Health and Family Welfare (MoHFW). This enclosed list specifies approved indications, primarily focusing on hematopoietic stem cell transplantation (HSCT). However, mesenchymal stem cell transplantation is not currently recommended for any disease condition as standard care. Therefore, practitioners must verify indications carefully. Moreover, the Supreme Court emphasized that patient consent alone cannot legitimize unproven treatments.

Stem Cell Research: Navigating the Regulatory Landscape

Beyond approved indications, stem cell therapy is permissible only within a research context. Consequently, strict regulatory oversight applies. If stem cells undergo more than minimal manipulation, the Central Drugs Standard Control Organization (CDSCO) regulates the research. Conversely, research involving less than minimal manipulation falls under the Department of Health Research (DHR). Additionally, these trials must receive approval from the National Stem Cell Research Regulation Committee. This complements the recommendations of Institutional Ethics Committees (IECs) registered with DHR. The CDSCO has clearly defined the levels of manipulation for stem cell therapy, guiding this classification. Therefore, adherence to these classifications is essential for all researchers.

Ethical Guidelines and Compliance for Clinical Trials on Stem Cell Therapy

Significantly, all stem cell therapy in India research must be conducted as part of an approved clinical trial. This mandates compliance with all ICMR ethical guidelines, which include obtaining written informed consent from patients. Furthermore, patients participating in these trials must incur no cost. Provisions for compensation in cases of injury or death are also mandatory. Therefore, ethical considerations are paramount in all research endeavors. Any stem cell treatment not aligning with the standard care indications, or lacking approval from CDSCO or DHR, will be deemed illegal and subject to legal action. This emphasizes the critical need for compliance to protect patients. For more on ethical medical practices, click here.

Approved Conditions for Hematopoietic Stem Cell Transplantation

The MoHFW's list of approved disease conditions for HSCT as standard care is extensive. For adults, conditions include various forms of leukemia (e.g., Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute lymphoblastic leukemia), lymphomas (e.g., Hodgkin's Lymphoma, Diffuse Large B cell lymphoma), myelodysplastic syndromes, and aplastic anemias. Additionally, multiple sclerosis and systemic sclerosis are also approved. For pediatric patients, the list includes similar leukemias and lymphomas, myelodysplastic syndromes, primary immunodeficiency diseases, thalassemia, and neuroblastoma. For complete details, refer to the Hematopoietic Cell Transplantation Guidelines 2021.

This advisory applies to all registered medical practitioners, medical colleges, and affiliated institutions. Consequently, deviations from these guidelines will lead to regulatory and legal action. This ensures robust oversight of stem cell therapy in India, safeguarding patient welfare. Therefore, comprehensive understanding and adherence are crucial for the medical community.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. National Medical Commission & Indian Council of Medical Research. Advisory: Compliance with Hon'ble Supreme Court Judgement dated 30.01.2026. Dated 25th March 2026.
2. Supreme Court: Stem cell therapy for Autism cannot be offered as routine/commercial clinical treatment. SCC Online. February 3, 2026.
3. Supreme Court Bars Stem Cell Therapy for Autism. Drishti IAS. February 9, 2026.